Recurrent Childhood Soft Tissue Sarcoma Recruiting Phase 2 Trials for Erdafitinib (DB12147)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03210714Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)Treatment